Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
SOLANA BEACH, Calif. , March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide) nasal spray, announced that Matthew J.
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Fiscal year 2023 net   product   sales   from   prescriptions totaled approximately $5.2M , a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
View HTML
Toggle Summary Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
SOLANA BEACH, Calif. , March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, today announced that the Company is scheduled to
View HTML
Toggle Summary Evoke Pharma Announces Closing of $7.5 Million Public Offering
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full SOLANA BEACH, Calif. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
SOLANA BEACH, Calif. , Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),  a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide) nasal spray, announced today that it has priced an
View HTML
Toggle Summary Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
GIMOTI now holds four listed patents with coverage through 2029 SOLANA BEACH, Calif. , Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),  a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®
View HTML
Toggle Summary United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2023 Financial Results
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in
View HTML
Toggle Summary Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide SOLANA BEACH, Calif. , Oct.
View HTML
Toggle Summary Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An
Selected for a Distinguished Oral Plenary Presentation SOLANA BEACH, Calif. , Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide)
View HTML